Skip to main content

Table 2 Primary and secondary resistance mutations in the Integrase by Sanger population sequencing

From: Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure

Patient Major resistance mutation Accesory mutation Polymorphism mutation
1F N155H __ C56S, E85EG, L101I, S119P, T122I, H171Q, K173EK
1A N155H __ C56S, L101I, S119P, T122I, H171Q
2F N155H __ M50I, L68R, V71I, L101I, S119P, H171Q
2A N155H __ M50I, V71I, P90PS, L101I, S119P
3F __ L74I E96D, K111T, K160KT
3A __ L74I E96D, K111T, G123RS
4F __ G163GR L101I, I113V, G134E, V150AV
4A __ G163GR M50IM, L101I, I113V, V150A
5F __ L74IM M50V, V72I, K103R, K111T, A124T
5A __ L74I M50V, V72I, K103R, K111T
6F N155H T97A D55Y, V72I, K111T, I113V, S119R, G123S, A124N, T125A
6A __ __ V72I, K111T, I113V, S119R, G123S, A124N, T125A
6 UDS N155H (9.77 %) T97A (12.42 %) V72I(37.44 %), Y99C(4.65 %), T122I(12.56 %), K156N(14.35 %), E157A(15.35 %), K111T(39.53 %), I113V(29.3 %), S119R(37.44 %), G123S(97.21 %), A124N(43.26 %), T125A(45.58 %)
7F N155H V151I I113V, S119P, T122I, A124N, C130Y
7A N155H V151I G52P, S119PR, T122I, I161X
  1. Patients are indicated with the numbers 1 to 7; F relates to the time point of therapeutic failure (plasma RNA), A to the proviral DNA studies after virological suppression, and UDS to massive sequencing data